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entiation between benign and malignant neck masses.
Materials and methods: Thirty-two patients having neck masses underwent routine MRI of the
neck as well as Hydrogen 1 (1H) MR spectroscopy with echo time of 270 ms at 1.5 T. Peak ampli-
tudes of choline (Cho) & creatine (Cr) for each lesion as well as normal appearing muscle of the
neck were obtained. Results were compared by using a nonparametric t test.
Results: Thirty-two lesions were included (14 benign) & (18 malignant). Mean value (±standard
deviation) was 4.42 ± 0.83 for malignant tumors and 1.93 ± 0.74 for benign tumors. Also spectra
were obtained from normal appearing muscles with average Cho/Cr ratio 1.59 ± 0.49. Differences
were signiﬁcant between benign & malignant tumors as well as between malignant tumors & normal
appearing muscles (p value < 0.001). No signiﬁcant difference could be detected between benign
tumors & normal appearing muscles (p value = 0.91).
Conclusion: MR spectroscopy should be used in the future as a complementary method to routine
MRI to differentiate between benign and malignant lesions.
 2012 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
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Patients with neck masses frequently present to the radiolo-
gist for further evaluation. The main role of the radiologist
is to differentiate between benign & malignant conditions
using different imaging modalities such as ultrasound with
color Doppler, CT and MRI. Where appropriate, the radiol-
ogist will also stage lesions for management purposes and
aid in guiding aspiration or biopsy. Sometimes, it is quite
difﬁcult to discriminate benign versus malignant lesion
depending on conventional radiology. Functional MRI has
emerged as a new method to help in solving such problems.
It has the unique ability to depict tissues at a cellular level
non-invasively (1).Production and hosting by Elsevier B.V.
4.006
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including detection of malignancy, grading tumor, predicting
response to treatment, monitoring treatment response, and
identifying persistent or recurrent disease. The ﬁrst step in this
process requires the identiﬁcation of spectra associated with
speciﬁc cancers (2). The results of hydrogen 1 (1H) MR spec-
troscopy have been reported in a few articles of in vivo cancer
series in the head and neck region (1).
The purpose of this study was to evaluate the role of MR
spectroscopy in differentiation between benign and malignant
neck masses.2. Subjects and methods
This is a prospective study. Thirty-two patients were included
in this study after taking oral approval. They were 12 females,
20 males (mean age was 37.5 years, range 1–74 years).
Patients with clinical suspicion of having neck masses, or
proved by other imaging modalities to have neck masses (CT
or ultrasonography), yet still need further evaluation were re-
ferred to the MRI unit Mansoura university hospital from
Ear, nose and throat surgery and also to radiotherapy depart-
ments, Mansoura University Hospital. Cases who are under
chemo or radiotherapy were not included in this study, also
cases did biopsy after MRI examination to avoid disturbance
of the lesion metabolites by hemorrhage or trauma.
2.1. Methods
2.1.1. Imaging
Magnetic resonance imaging of the neck was performed on a
1.5 Tesla at MRI Unit, Mansoura University Hospital.
All patients were examined in the same position used for
routine MRI examination of the neck using head coil.
Conventional MRI sequences as well as functional MRI
techniques were used for all patients.
The standard imaging protocol consisted of the following se-
quences: localizing sagittal T1-weighted (TR/TE/NEX: 300/
14ms/1), axial T1-weighted (TR/TE/NEX: 500/15ms/1), and fast
spin-echo axial T2-weighted (TR/TE/NEX: 4490/85ms/1). Post
contrast axial, coronal and sagittal T1 images were obtained
after manual injection of 10 mL of gadopentetate dimeglumine.
For all the above sequences, the slice thickness was 5 mm
with interslice gap of 1 mm, FOV was 220–240 mm, and the
matrix was 128 · 256.
2.2. Proton MR spectroscopy
All patients underwent Chemical shift imaging (CSI).
Localization of the ROI depended primarily on the appear-
ance of the lesions in the preceding pre and post contrast MR
images.
Water suppression of the dominant water signal by CHESS
technique, outer volume fat suppression as well as magnetic
shimming were performed automatically for all patients at
the beginning of both SVS & CSI examinations. Curve ﬁtting
was done automatically for all obtained spectra.
The time domain signal intensity was apodized and pro-
cessed to remove the residual water signal. Post-processing
of the spectroscopic data consisted of frequency shift andphase and linear baseline corrections after Fourier
transformation.
In most cases, these processes were automatic. Frequency
domain curve was ﬁtted to Gaussian line shape by using the
software provided by the manufacturer to deﬁne choline-con-
taining components (Cho), and creatine and phosphocreatine
(Cr) peaks.
Metabolic peak used in the differentiation of different tissue
types was that of Cho at 3.22 ppm.
2.2.1. Pathological examination
Surgical excision was done for 20 cases, FNAC was done for
the remaining 12 cases.
2.2.2. Statistical analysis
Statistical analysis was done using SPPS for windows version
17.
The level of signiﬁcance was set at P 6 0.05.
3. Results
Tables 1–3.
Cho/Cr ratios were obtained in 32 lesions, with a mean value
(±standard deviation) of 4.42 ± 0.83 for malignant tumor,
1.93 ± 0.74 for benign tumors. Also spectrawere obtained from
normal appearing muscles in 32 patients with average Cho/Cr
ratio 1.59 ± 0.49. Differences were signiﬁcant between benign
&malignant tumors aswell as betweenmalignant tumors&nor-
mal appearing muscle. No signiﬁcant difference could be de-
tected between benign tumors & normal appearing muscles.
There was mild overlap between benign mixed salivary
gland tumor and one case of adenoid cystic carcinoma of the
parotid gland. Cutoff value in our study was 3 with sensitivity
of 94% and speciﬁcity 86%.
High Lipid peaks were detected in both malignant and be-
nign lesions, we did not include their values in the statistics of
this study as we thought they represent contamination from
adjacent tissue.
Also we were not able to separate Lipid from Lac peaks
owing to software defect in our device.
3.1. Case 1
Female patient aged 47 y with history of cancer breast, pre-
senting with left orbit metastatic deposit (Fig. 1a and b).
3.2. Case 2
Female patient aged 67 y with SCC of the base of the tongue
(Fig. 2a and b).
3.3. Case 3
Male patient 37 y with malignant minor salivary gland tumor
(Fig. 3a and b).
3.4. Case 4
Female patient aged 65 y with DM who had extensive right
masticator space chronic non speciﬁc infection (Fig. 4a and b).
Table 1 Different types of malignant and benign lesions
included in this study and their corresponding Cho/Cr ratio.
Type of lesion Number Cho/Cr
A-malignant
Lymphoma 5 5.4 ± 1.3
Adenocarcinoma of the minor
salivary glands
5 3.9 ± 1.7
Nasopharyngeal carcinoma 4 4.1 ± 0.53
Adenocarcinoma of the ethmoid
sinus
1 5.4
Cystic adenoid carcinoma 1 2.7
Metastases from cancer breast 1 3.5
SCC of the tongue 1 5.1
Mean 4.42 ± 0.83
B-benign lesions
Benign mixed salivary gland tumor 4 2.8 ± 0.7
Nasopharyngeal angioﬁbroma 3 1.4 ± 1.2
Non speciﬁc inﬂammation 2 1.7 ± 0.83
Thyroglossal duct cyst 2 1.1 ± 0.35
Inﬂammatory LNs 2 1.4 ± 1.1
Schwannoma 1 3.2
Mean 1.93 ± 0.74
Table 2 mean Cho/Cr ratio for each group of lesions.
Group Mean ± SD
Malignant 4.42 ± 0.83
Benign 1.93 ± 0.74
Normal appearing muscles 1.59 ± 0.49
Table 3 P values of Cho/Cr ratio between malignant, benign
lesions and muscles.
Comparison group P value
Benign lesions versus normal appearing muscles 0.91
Malignant lesions versus normal appearing muscles <0.001
Benign versus malignant <0.001
Statistically signiﬁcant difference (P< .05).
Fig. 1 (a) Coronal post contrast fat suppressed T1 WI revealed;
a large well deﬁned heterogeneously enhanced mass is seen
inﬁltrating the left greater wing of sphenoid bone with both
intra-orbital & intra-cranial extensions. (b) MRS revealed: high
Cho peak (7.75) detected at (3.2 ppm), white arrow points to Cho
peak, thick arrow points to Cr peak.
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Male patient aged 17 y with nasopharyngeal angioﬁbroma
(Fig. 5a and b).
3.6. Case 6
Male patient aged 7 y with left bacterial non speciﬁc parotitis
(Fig. 6a and b).
4. Discussion
Head and neck region comprises a variety of anatomic sites.
For example, tumors arising from the skin, nasal cavity and
paranasal sinuses, oral cavity, nasopharynx, oropharynx,
hypopharynx, larynx, esophagus, thyroid gland, salivary
glands, soft-tissue tumors, bone sarcomas, and miscellaneoustumors such as neurogenic tumors and paragangliomas are
all included in the head and neck region. The pre-operative
information on whether a tumor is benign or malignant may
be helpful to prevent treatment delay in the case of malignant
tumor and in patient counseling as to likely treatment and pos-
sible sequels (3).
For this purpose, in many instances, the conventional imag-
ing techniques such as computed tomography (CT), magnetic
resonance imaging (MRI) and ultrasonography (US) are of
limited accuracy (4). Consequently, there is a great need for
a high technology noninvasive imaging method that allows
the detection of head and neck malignancy more accurately.
1H MR spectroscopy has the potential to become another
tool in differentiating malignant from benign tumors. It has al-
ready an established technique for brain tumors and breast
and prostate cancer (5–7). Because this technique measures
the presence of speciﬁc metabolites, it is independent of ana-
tomic information and may be used to characterize lesions that
are indeterminate on standard anatomic studies (8).
Fig. 2 (a) Axial fat suppressed T2 WI revealed a large irregular
lobulated mass of high SI inﬁltrating the right posterolateral
aspect of the tongue. (b) MRS revealed: high Cho peak (9.36)
detected at (3.2 ppm), white arrow points to Cho peak, thick
arrow points to Cr peak.
Fig. 3 (a) Axial post contrast fat suppressed T1 WI revealed; a
large well deﬁned heterogeneously enhanced mass in the left
parapharyngeal space. (b) MRS revealed: high Cho peak (9.36)
detected at (3.2 ppm), white arrow points to Cho peak, thick
arrow points to Cr peak.
424 D.M. Fahmy et al.In the current study we did not limit case selection to cer-
tain pathological entities in the neck region. We aimed to eval-
uate the ability to use proton MR spectroscopy as a
differentiating tool as a general, based upon the idea that a
high Cho/Cr ratio is tied to a high cellular membrane turnover
in malignant lesions.
Typical spectral patterns associated with cancer include an
increase in the total choline (Cho, 3.2 ppm) signal intensity (SI)
relative to creatine (Cr, 3.0 ppm), often coupled with the pres-
ence of other metabolites, including lactate (Lac, 1.3 ppm) (1–
5). Both diagnostic and oncologic applications may be offered
by allowing for discrimination between regions of healthy tis-
sue, necrosis, and new growth or recurrence (9).
Choline and its derivatives are thought to originate from
phospholipid metabolism of cell membranes. The ﬁnding of
higher Choline metabolite levels indicates an increase in cell
proliferation and membrane biosynthesis in tumors. Similar
results have been obtained from prostate, brain, colon, breast,
thyroid, adrenal and neck masses (7,10–13) and it is possible
that it can be used as a marker for active cellular proliferation.
The high Cho/Cr ratio of cancer compared with that of normalmuscle has also been observed in cases of squamous cell carci-
noma of the extracranial head and neck (14). On the other
hand it was suggested that there is a possible decrease in the
creatine levels consistent with an increased rate of metabolism
(i.e., an increased energy consumption) in tumors that are
highly aggressive (14).
We found that Cho/Cr ratio was signiﬁcantly higher in
malignant tumors than in muscles and benign lesions as well.
Malignant lesions showed a mean value (±standard deviation)
of 4.42 ± 0.83, as compared with 1.93 ± 0.74 for benign tu-
mors and 1.59 ± 0.49 for normal appearing muscles. Similar
results were obtained in other studies by Mukherji et al. (1)
(Cho/Cr ratio of 0–1.16 at TE 136) and Star-Lack et al. (15)
(lymph node Cho/Cr = 2.9 ± 1.6, muscle Cho/Cr = 0.55 ±
0.210 at TE 144). The high Cho/Cr ratio of cancer compared
with that of normal muscle has also been observed in cases
of squamous cell carcinoma of the extracranial head and neck
(1,14,16–18), with a reported Cho/Cr range of 1.8–7.2. High
Cho values were also noticed in nodal metastases (18,19).
Fig. 4 (a) Axial post contrast T1 fat suppressed image revealed;
a large ill deﬁned heterogeneously enhanced lesion inﬁltrating the
masticator space extending into the right maxillary sinus &
eroding the ramus of the mandible. Small marginally enhanced
locule is seen at its anterior aspect. (b) MRS revealed: prominent
Cho peak detected at (3.2 ppm), low value 2.9.
Fig. 5 (a) Axial & sagittal post contrast T1 WI revealed; large
intensely enhancing mass primarily originating from the naso-
pharynx extending into the right nasal cavity. (b) MRS revealed:
prominent Cho peak detected at (3.2 ppm), of low value 1.3 (white
arrow points to Cho peak, thick arrow points to Cr peak).
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neck squamous cell carcinoma and metastatic lymph nodes
(2.23 and 2.34, respectively), have also reported signiﬁcant cor-
relation between these ratios and certain biomarkers such as
epidermal growth factor receptor (EGFR) and cyclo-oxygen-
ase 2 (COX-2).
On the contrary other studies reported higher Cho/Cr in
benign tumors than in muscle and malignant lesions (8,20).
As Maheshwari et al. (8) found that the average Cho/Cr ratio
for benign lesions was 3.92 (TE = 136) and 6.11 (TE = 272)
while it was 1.16 and 1.31 for muscles at TE 136 & 272 respec-
tively, whereas for SCCA the average Cho/Cr ratio at TEs of
136 and 272 was 1.67 and 2.45, respectively. Also King et al.
(20) reported higher Cho/Cr in benign salivary gland tumors
as compared to malignant ones. They have attributed these
results to the fact that an elevated Cho level, which is a marker
of membrane turnover, is found not only in malignant tumorsbut also in benign tumors that are hypercellular and in inﬂam-
matory processes (20).
In our study there was mild overlap between benign mixed
salivary gland tumor and one case of adenoid cystic carcinoma
of the parotid gland which could be explained by hypercellu-
larity of benign mixed salivary gland tumors as previously
reported by King et al. (20). Cutoff value in our study was 3
with sensitivity of 94% and speciﬁcity of 86%.
Other researchers found difﬁculty in detecting Cr peak, and
attained other methods to differentiate lesions. Gupta et al.
(13), focused their study on detecting high Cho peak only.
They have found high Cho peak in all malignant follicular car-
cinomas that were included in their study, and only one case of
benign follicular adenoma with sensitivity of 100%, while the
speciﬁcity was 94.11%. Others tried to measure Cho/noise ra-
tio and used it instead of Cho/Cr ratio, like Yua et al. (21) and
Bartella et al. (10). Yua et al. (21) who had classiﬁed lesions
into three categories: type1; lesions with the absence of Cho
signals, type 2; lesions with Cho signals and a Cho/noise ratio
<3, and type 3; lesions with Cho signals and a Cho/noise ratio
>3. They had a sensitivity of 76.5%, speciﬁcity of 100%, po-
sitive predictive value of 100%, negative predictive value of
63.6%, and accuracy of 83.3% on considering type 3 lesions
as malignant tumors.
Other researchers (22) had connected high Cho peak de-
tected in SCC lesions with grave tumor response to therapy,
Fig. 6 (a) Axial post contrast T1 fat suppressed image revealed;
diffusely swollen left parotid gland with homogenous enhance-
ment. (b) MRS revealed: prominent Cho peak was detected at
(3.2 ppm), yet medium value 4.4 (straight arrow points to Cho
peak, while thick arrow points to Cr peak.
426 D.M. Fahmy et al.which by indirect way indicates a high grade of malignancy.
They have suggested that MR spectroscopy may be a simple
method for predicting tumor behavior. In our study we did
not follow malignant cases to verify this issue.
In addition to Cho and Cr peaks, broad lipid signals were
also detected in most malignant as well as benign masses spec-
tra. This copes with Smith et al. (23) who reported that the sig-
niﬁcance of these lipid peaks is uncertain because they are
associated not only with malignancy but also with necrosis,
inﬂammation, and benign cellular processes. It is unclear
whether the bulk of these detected lipids originated from with-
in the cancer or was caused by signal intensity contamination
from adjacent fatty tissues (23).
As regard using Lactate peak to differentiate abscess from
malignant lesions, it was not applicable in this study for several
reasons. First lactate resonates (1.32 ppm) in the same region
as lipids (0.90–2.02 ppm), and, since these fatty acid signals
were very broad (12.2 Hz ± 2.4) and intense, weak signalcontribution from lactate might have been overshadowed by
that from lipids (20). Also there was a defect in our software
made it inefﬁcient in detecting and separating lactate and
aspartate peaks.
On the other hand controversial results were reported as re-
gard lactate Le et al. (24) reported that the lactate SI could not
be used as hypoxia indicator as it did not correlate with tumor
pO2, treatment response, or locoregional control. While Star-
Lack et al. (15) stated that tissue hypoxia and pO2 levels were
correlated with tumor lactate indicating the use of 1H MRS in
monitoring oxygenation of head and neck tumors and squa-
mous cell carcinoma tumors.
Beside inability to detect aspartate and lactate peaks in
inﬂammatory lesions, there were other technical difﬁculties
and limitations in this study. First of all a small number of le-
sions were included in the study as compared to the large path-
ological entities present in the neck region. Unavoidable
inclusion of adjacent bony and air-containing structures in
the large VOI which reduced the likelihood of obtaining an
adequate shim and resulted in decreased spectral resolution.
The presence of high lipid concentrations could have corrupted
metabolite intensity measurements. Also we did not examine
the technique on small volume lesions (<1 cm3).
5. Conclusion
MR spectroscopy is a useful non-invasive imaging modality
which can aid in the differentiation between benign & malig-
nant neck masses.References
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